Association of SLC22A1, SLC47A1, and KCNJ11 polymorphisms with efficacy and safety of metformin and sulfonylurea combination therapy in Egyptian patients with type 2 diabetes
Authors:
Open Access
- 23 November 2023
- journal article
- research article
- Published by Medknow in Research in Pharmaceutical Sciences
- Vol. 18 (6) , 614-625
Abstract
Background and purpose: Multidrug and toxin extrusion transporter 1 (MATE1), encoded by the SLC47A1 gene and single nucleotide polymorphisms of organic cation transport 1, may impact metformin's responsiveness and side effects. Inward-rectifier potassium channel 6.2 (Kir 6.2) subunits encoded by KCNJ11 may affect the response to sulfonylurea. This study aimed to evaluate the association between SLC22A1 rs72552763 and rs628031, SLC47A1 rs2289669 and KCNJ11 rs5219 genetic variations with sulfonylurea and metformin combination therapy efficacy and safety in Egyptian type 2 diabetes mellitus patients. Experimental approach: This study was conducted on 100 cases taking at least one year of sulfonylurea and metformin combination therapy. Patients were genotyped via the polymerase chain reaction-restriction fragment length polymorphism technique. Then, according to their glycated hemoglobin level, cases were subdivided into non-responders or responders. Depending on metformin-induced gastrointestinal tract side effects incidence, patients are classified as tolerant or intolerant. Findings/Results: KCNJ11 rs5219 heterozygous and homozygous mutant genotypes, SLC47A1 rs2289669 heterozygous and homozygous mutant genotypes (AA and AG), and mutant alleles of both polymorphisms were significantly related with increased response to combined therapy. Individuals with the SLC22A1 (rs72552763) GAT/del genotype and the SLC22A1 (rs628031) AG and AA genotypes were at a higher risk for metformin-induced gastrointestinal tract adverse effects. Conclusion and implications: The results implied a role for SLC47A1 rs2289669 and KCNJ11 rs5219 in the responsiveness to combined therapy. SLC22A1 (rs628031) and (rs72552763) polymorphisms may be associated with increased metformin adverse effects in type 2 diabetes mellitus patients.Keywords
This publication has 57 references indexed in Scilit:
- KCNJ11 gene E23K variant and therapeutic response to sulfonylureasEuropean Journal of Internal Medicine, 2012
- Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetesTherapeutic Advances in Endocrinology and Metabolism, 2011
- Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patientsPharmacogenetics and Genomics, 2011
- Genetic analysis of OCT1 gene polymorphisms in an Indian populationIndian Journal of Human Genetics, 2011
- Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered FunctionThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Expression of Organic Cation Transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) Is Affected by Genetic Factors and Cholestasis in Human Liver†Hepatology, 2009
- Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS StudyDiabetes, 2009
- Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary StudyDiabetes, 2009
- Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin PharmacokineticsClinical Pharmacology & Therapeutics, 2007
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJournal of Clinical Investigation, 2007